Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of LY3493269 in Type 2 Diabetes
NCT04515576Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3493269 in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Treatment-Emergent Adverse Events at Day 57. Started Aug 2020; status: completed.
02
Drugs
LY3493269
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04515576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515576.